TORONTO, ON / ACCESSWIRE / November 12, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) (“Novamind”), a leading mental health company specialized in psychedelic medicine, announced today it has leased a new clinic location in Utah (the “Wheeler Park Clinic”), and will relocate the Company’s Millcreek clinic to the Wheeler Park Clinic to better serve a growing patient base.
“Wait times to book new appointments at all Novamind clinics reflect the growing demand for our unique treatments and services,” said Pierre Bou-Mansour, Novamind’s Chief Operating Officer.
He continued, “As we scale our clinic footprint to meet that demand, we are equally committed to optimizing the patient experience and elevating the standard of care. The Wheeler Park Clinic is a great example of a space that aligns with that vision. It’s easily accessible, modern and enables the right therapeutic environment for our clients and clinicians.”
With minimal leasehold improvements, the Wheeler Park Clinic is anticipated to open in early 2022.
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Samantha DeLenardo, VP, Communications
Email: [email protected]
Bill Mitoulas, Investor Relations
Email: [email protected]
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
SOURCE: Novamind Inc.
View source version on accesswire.com: